Mdxhealth, Inc.
Irvine, CA
- UEI
- LQGYDJJ9K8Q6
- CAGE
- 7F2H8
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
- Waltham, MA TCKUCULVVY39
-
- SAM.gov registration date
- Physical address
- 15279 Alton Pkwy #100, Irvine, CA 92618, USA
- Website
- mdxhealth.com
- Founded
- 2004
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $283,920 |
| FY2025 | $497,453 |
| FY2024 | $671,210 |
| FY2023 | $626,010 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $283,920 |
Contract vehicles
No active vehicles.
1 expired vehicle
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Exosome Diagnostics Inc. | Waltham, MA | 621511 Medical Laboratories |
| Genomic Health, Inc. | Redwood City, CA | 621511 Medical Laboratories |
| Exact Sciences Laboratories, LLC | Madison, WI | 621511 Medical Laboratories |
| Biocartis US Inc. | Itasca, IL | 334516 Analytical Laboratory Instrument Manufacturing |
| Veracyte, Inc. | South San Francisco, CA | 621511 Medical Laboratories |
About the company
Mdxhealth, Inc., a for-profit healthcare company headquartered in Irvine, California, delivers molecular diagnostic testing services for cancer to the Department of Veterans Affairs as a prime contractor under the GSA Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II). The company operates across 60 prime awards (100% of its federal footprint) with no subcontract work, competing predominantly in full-and-open procurement with partial small-business set-aside exposure on specific vehicles. Mdxhealth is foreign-owned; it maintains a named subsidiary, Exosome Diagnostics Inc.
The vendor's capability portfolio concentrates on specialized molecular diagnostic testing for prostate cancer screening and treatment planning, delivered through proprietary genomic and epigenetic analysis platforms. Representative offerings include Oncotype DX Prostate testing, Genomic Prostate Score (GPS) testing, DX Prostate Testing, and MDX Health Testing services. Concrete work includes a $6.4 million single-award BPA with Veterans Integrated Service Network 17 for Oncotype DX prostate testing services (awarded May 2023, running through April 2028), a $755,655 total-small-business BPA with VISN 8 for prostate cancer testing through June 2027, and a $1.424 million single-award BPA with VISN 19 for MDX Health Testing services (awarded October 2025, running through September 2030). Recent BPA calls include a $62,667.50 call from VISN 8 for prostate cancer testing (Option 4) and a $243,668.52 call from VISN 19 for MDX Health Testing, both awarded in July 2026.
Customer concentration sits almost entirely within the VA system. The five most active VISN customers account for 92% of awards by count. VISN 17 and VISN 19 anchor the portfolio: VISN 17 holds 16 awards with $8.6 million in combined potential value, while VISN 19 holds 22 awards with $4.5 million. VISN 8 carries 9 awards ($2.3 million), VISN 10 carries 5 awards ($123 thousand), and VISN 21 carries 3 awards ($1.3 million). By potential value, VISN 17 leads with $8.6 million, followed by VISN 19 at $4.5 million and VISN 12 (a single-award outlier) at $3.2 million. The two rankings track closely—dollar concentration mirrors award volume—and indicate high dependence on a handful of VA regional networks rather than agency diversification.
All 86 task orders flow through the Medical Laboratory Testing and Analysis Services Federal Supply Schedule, with combined potential value of $19.2 million. Mdxhealth holds six active single-award BPAs under the schedule: the $6.4 million VISN 17 Oncotype DX agreement, the $755,655 VISN 8 prostate cancer testing BPA (total-small-business set-aside), a $640,000 VISN 17 DX Prostate Testing BPA, a $420,000 VISN 17 DX Prostate Testing BPA, a $320,000 VISN 17 Genomic Prostate Score BPA, and the $1.424 million VISN 19 MDX Health Testing BPA. One additional delivery order vehicle (IDC 36C25020D0022) carries minimal value ($2 thousand across four orders).
Activity has grown modestly from four awards in 2022 to nine in 2025, with four awards recorded in 2026 year-to-date. Four awards with combined potential value of $106 thousand are scheduled for completion within the next twenty-four months, representing limited near-term recompete exposure but flagging annual recompete cycles common to VA BPA vehicles. Combined potential value across all awards stands at $19.9 million, with $3 million obligated (15% utilization rate), indicating early-stage drawdown against available ceilings.
The vendor's capability focus—molecular diagnostic testing, genomic and epigenetic analysis, personalized cancer screening and treatment planning—is narrow and specialized, concentrating entirely within one federal customer (VA), one procurement vehicle (FSS-621-II), and one disease category (prostate cancer). Six of nine active BPAs explicitly name prostate cancer or MDX Health Testing. The small-business set-aside presence is confined to the VISN 8 relationship; the remainder compete full-and-open.
Quick answers
Is Mdxhealth, Inc. registered in SAM.gov?
Yes. Mdxhealth, Inc.'s SAM.gov registration is active through October 12, 2027.
Which contract vehicles does Mdxhealth, Inc. hold?
Mdxhealth, Inc. holds a place on 1 federal contract vehicle: FSS-621-II.
How much has Mdxhealth, Inc. received in federal contracts?
Federal contracts obligated $497,453 to Mdxhealth, Inc. in fiscal year 2025 and $2,078,593 in fiscal years 2023 through 2027.
How does Mdxhealth, Inc. rank among federal contractors?
Mdxhealth, Inc. ranked #72 in NAICS 621511 and #94 in NAICS 6215 in FY2025.
What is Mdxhealth, Inc.'s most recent federal award?
Mdxhealth, Inc.'s most recent federal contract award is Do prostate cancer test- do option 4 (36C24826N0634), from Veterans Integrated Service Network 8 (VHA), on July 10, 2026.
On GovTribe
See Mdxhealth, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors